Kamble Rammurti T, Selby George B, Mims Martha, Kharfan-Dabaja Mohamed A, Ozer Howard, George James N
Oklahoma University Health Sciences Center, Oklahoma City, Oklahama 73190, USA.
Biol Blood Marrow Transplant. 2006 May;12(5):506-10. doi: 10.1016/j.bbmt.2006.01.004.
Iron overload presenting as exacerbation of hepatic graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation has not been previously described. We report 6 patients with established hepatic GVHD in whom iron overload (median serum ferritin, 7231 mug/dL; median transferrin saturation, 77%) resulting from a lifetime median of 20 units of packed red blood cell transfusions was manifested by worsening of liver function. Liver biopsies performed in 4 patients confirmed severe iron overload and also hepatic GVHD. Analysis for the C282Y and H63D hemochromatosis gene mutation was negative for the homozygous state in all 6 patients. Erythropoietin-assisted phlebotomy resulted in normalization of liver function at a median of 7 months and of serum ferritin at a median of 11 months. Immunosuppressive therapy was successfully tapered in all 4 patients who completed the phlebotomy program, and this supported the impression that iron overload, rather than GVHD, was the principal cause of liver dysfunction. At a median follow-up of 50 months (range, 18-76 months) from the transplantation and 25 months (range, 5-36 months) from ferritin normalization, all 4 patients require maintenance phlebotomy. We conclude that iron overload can mimic GVHD exacerbation, thus resulting in unnecessary continuation or intensification of immunosuppressive therapy for GVHD, and that maintenance phlebotomy is necessary after successful iron-reduction therapy.
铁过载表现为异基因造血干细胞移植后肝移植物抗宿主病(GVHD)的加重,此前尚未见报道。我们报告了6例已确诊肝GVHD的患者,其铁过载(中位血清铁蛋白7231μg/dL;中位转铁蛋白饱和度77%)由终生中位20单位的浓缩红细胞输注引起,表现为肝功能恶化。4例患者进行的肝活检证实存在严重铁过载及肝GVHD。所有6例患者的C282Y和H63D血色素沉着症基因突变分析均未发现纯合状态。促红细胞生成素辅助静脉放血治疗使肝功能在中位7个月时恢复正常,血清铁蛋白在中位11个月时恢复正常。所有4例完成静脉放血治疗方案的患者免疫抑制治疗均成功减量,这支持了铁过载而非GVHD是肝功能障碍主要原因的观点。自移植后中位随访50个月(范围18 - 76个月),自铁蛋白正常化后中位随访25个月(范围5 - 36个月),所有4例患者均需维持静脉放血治疗。我们得出结论,铁过载可模拟GVHD加重,从而导致对GVHD进行不必要的免疫抑制治疗的持续或强化,且成功的铁减少治疗后维持静脉放血治疗是必要的。